Hanmi Pharmaceutical is showing an upward trend in stock prices despite poor business performance in the first quarter of this year. This is interpreted as investors' focus on the significant increase in export performance and the high potential for future earnings growth.
As of 9:45 a.m. on the 30th, Hanmi Pharmaceutical is trading at 272,500 won, up 25,500 won (10.32%) compared to the previous trading day.
Hanmi Pharmaceutical announced on the 29th that it achieved consolidated revenue of 390.9 billion won and operating profit of 59 billion won in the first quarter. Compared to the same period last year, revenue decreased by 3.2% and operating profit by 23%.
However, the increase in export performance is noticeable. Hanmi Pharmaceutical's export performance in the first quarter was 68.2 billion won, a 46.7% increase compared to the same period last year. A Hanmi Pharmaceutical official noted, "The supply of clinical products for the MASH new drug candidate being developed by MSD in the U.S. has expanded," and added, "We are focusing on expanding partnerships and cooperation product lines beyond North America and Japan to the Middle East and Latin America."